Bezlotoxumab
- Generic Name
- Bezlotoxumab
- Brand Names
- Zinplava
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1246264-45-8
- Unique Ingredient Identifier
- 4H5YMK1H2E
- Background
Bezlotoxumab is a fully humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. First approved by the FDA on October 21, 2016, bezlotoxumab is used to reduce the recurrence of C. difficile infection. On November 22, 2016, the Committee for Medicinal Products for Human Use of the Eur...
- Indication
Bezlotoxumab is indicated to reduce the recurrence of Clostridioides difficile infection (CDI) in patients who are receiving antibacterial drug treatment for CDI and are at high risk for CDI recurrence. In the US, the drug is approved for use in patients one year of age and older. In Europe, it is approved in adults only.
- Associated Conditions
- Clostridium difficile infection recurrence
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.